- Home
- FFIE vs NRBO Comparison
FFIE vs NRBO Comparison
Compare FFIE & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIE
- NRBO
- Stock Information
- Founded
- FFIE 2014
- NRBO N/A
- Country
- FFIE United States
- NRBO United States
- Employees
- FFIE N/A
- NRBO N/A
- Industry
- FFIE Auto Manufacturing
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- FFIE Consumer Discretionary
- NRBO Health Care
- Exchange
- FFIE Nasdaq
- NRBO Nasdaq
- Market Cap
- FFIE 26.7M
- NRBO 27.9M
- IPO Year
- FFIE N/A
- NRBO N/A
- Fundamental
- Price
- FFIE $1.40
- NRBO $2.46
- Analyst Decision
- FFIE
- NRBO Strong Buy
- Analyst Count
- FFIE 0
- NRBO 1
- Target Price
- FFIE N/A
- NRBO $10.00
- AVG Volume (30 Days)
- FFIE 6.2M
- NRBO 34.1K
- Earning Date
- FFIE 11-06-2024
- NRBO 11-07-2024
- Dividend Yield
- FFIE N/A
- NRBO N/A
- EPS Growth
- FFIE N/A
- NRBO N/A
- EPS
- FFIE N/A
- NRBO N/A
- Revenue
- FFIE $537,000.00
- NRBO N/A
- Revenue This Year
- FFIE $10,958.67
- NRBO N/A
- Revenue Next Year
- FFIE $617.65
- NRBO N/A
- P/E Ratio
- FFIE N/A
- NRBO N/A
- Revenue Growth
- FFIE N/A
- NRBO N/A
- 52 Week Low
- FFIE $1.35
- NRBO $2.08
- 52 Week High
- FFIE $156.00
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- FFIE 26.29
- NRBO 39.90
- Support Level
- FFIE $1.81
- NRBO $2.37
- Resistance Level
- FFIE $1.65
- NRBO $2.99
- Average True Range (ATR)
- FFIE 0.16
- NRBO 0.30
- MACD
- FFIE 0.02
- NRBO 0.00
- Stochastic Oscillator
- FFIE 10.66
- NRBO 22.22
About FFIE Faraday Future Intelligent Electric Inc.
Faraday Future Intelligent Electric Inc is a global shared intelligent mobility ecosystem. It is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.